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Abstract
Background: While the majority of germline inactivating mutations in BRCA1/2 are small-scale mutations, large
genomic rearrangements (LGRs) are also detected in a variable proportion of patients. However, routine genetic
methods are incapable of detecting LGRs, and comprehensive genetic testing algorithm is necessary.
Methods: We performed multiplex ligation-dependent probe amplification assay for small-scale mutation negative
patients at high-risk for LGR, based on previously published LGR risk criteria. The inclusion criteria for the high-risk
subgroup were personal history of 1) early-onset breast cancer (diagnosed at ≤36 years); 2) two breast primaries; 3)
breast cancer diagnosed at any age, with ≥1 close blood relatives (includes first-, second-, or third-degree) with
breast and/or epithelial ovarian cancer; 4) both breast and epithelial ovarian cancer diagnosed at any age; and 5)
epithelial ovarian cancer with ≥1 close blood relatives with breast and/or epithelial ovarian cancer.
Results: Two LGRs were identified. One was a heterozygous deletion of exon 19 and the other was a heterozygous
duplication of exon 4–6. The prevalence of LGRs was 7% among Sanger-negative, high-risk patients, and accounted
for 13% of all BRCA1 mutations and 2% of all patients. Moreover, LGRs reported in Korean patients, including our 2
newly identified cases, were found exclusively in families with at least one high-risk feature.
Conclusions: Our result suggests that selective LGR screening for Sanger-negative, high-risk patients is necessary
for Korean patients.
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Background
Breast cancer was the second most common cancer in
females aged 15–64 in Korea [1] and in 2013, a total of
17,292 incident breast cancer cases were reported in
Korea Central Cancer Registry [2]. Breast cancer inci-
dence in Korea has markedly increased in recent years,
and the crude incidence of breast cancer in Korea is the
highest among Asian countries [3]. Also, the average age
at onset of breast cancer is 10 years earlier than Western
populations. A younger age at diagnosis suggests that
genetic susceptibility genes may be involved in a sub-
stantial proportion of breast cancer in Korea.
Recently, genetic counselling and genetic testing of
BRCA1 and BRCA2 for the presence of germline inactivat-
ing mutations have been increasingly offered to identify in-
dividuals at elevated risk of breast and ovarian cancer in
Korea. According to a large nationwide prospective Korean
Hereditary Breast Cancer (KOHBRA) study, 153 distinct
BRCA1/2 mutations have been identified in Korean breast
cancer patients with a family history of breast/ovarian
cancer resulting in a prevalence of 22.3% [3].
However, until recently, testing of BRCA1 and BRCA2
mutations has been focused on the identification of
small-scale mutations (point mutations, small deletions
* Correspondence: chez@catholic.ac.kr
1Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of
Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu,
Seoul 06591, Republic of Korea
3Catholic Genetic Laboratory Center, Seoul St. Mary’s Hospital, College of
Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. BMC Medical Genetics  (2017) 18:38 
DOI 10.1186/s12881-017-0398-3
and insertions). Such mutations occur throughout the
whole coding sequence and at the splice junctions of
both genes. They result in protein truncation, disruption
of messenger RNA processing, or amino acid substitu-
tions that have significant impact on protein function
and are readily detectable by standard methods of
Sanger sequencing of polymerase chain reaction (PCR)-
amplified gene segments [4]. Large genomic rearrange-
ment (LGR) of BRCA1 and BRCA2, which is another
mechanism of gene inactivation, is responsible for a vari-
able but significant proportion of BRCA mutations [5].
High prevalence of LGRs in BRCA1 have been demon-
strated in several populations, including Dutch, Northern
Italian, French, and Czech, and in such populations, LGR
screening has been advocated as a cost-effective, initial
phase screening test [6]. In Korea, reported LGR cases are
few, and routine PCR-based genetic testing methods
are not capable of detecting LGRs. Therefore, an effi-
cient genetic testing algorithm that incorporates LGR
testing is necessary for accurate mutational screening
of high-risk patients.
Herein, we performed multiplex ligation-dependent
probe amplification (MLPA) for LGR analysis in a subset
of small-scale mutation negative patients who were also
stratified as high-risk for LGR based on previously pub-
lished LGR risk criteria from other ethnicities [5, 7].
Here we report the prevalence of the different type of
BRCA mutations according to risk stratification, to
provide evidence for developing an effective and com-
prehensive BRCA genetic screening strategy in Korean
patients.
Methods
Patients and clinical diagnosis
A total of 106 patients at risk for hereditary breast and
ovarian cancer (HBOC) and for whom mutation analysis
was requested from January 2015 to November 2015 at
Seoul St. Mary’s Hospital were included in this study. The
family history, past medical history, and tumor pathology
of the probands and their family members were detailed
by their referring physicians and/or through review of pa-
tient’s medical records. All participants gave informed
consent, and this study was approved by the Institutional
Review Board (IRB)/Ethics Committee of Seoul St. Mary’s
Hospital (IRB No.KC15RISI0915).
The referred patients all met the National Comprehen-
sive Cancer Network genetic testing criteria for HBOC
syndrome [8] and high-risk subgroup for LGR was de-
fined based on the previously published LGR risk criteria
[5, 7, 9]. The inclusion criteria for the high-risk sub-
group were personal history of 1) early-onset breast
cancer (diagnosed at ≤36 years); 2) two breast cancer
primaries; 3) breast cancer diagnosed at any age, with ≥1
close blood relatives (includes first-, second-, or third-
degree) with breast and/or epithelial ovarian cancer; 4)
both breast and epithelial ovarian cancer diagnosed at any
age; and 5) epithelial ovarian cancer with ≥1 close blood
relatives with breast and/or epithelial ovarian cancer.
Sanger sequencing
Sanger sequencing was performed in all patients to de-
tect small-scale mutations. Genomic DNA was isolated
from the peripheral blood leukocytes, using the QIAmp
DNA Mini Kit (Qiagen, Hamburg, Germany). Sanger se-
quencing was performed as described previously [10].
Exon numbering and DNA sequence variant descrip-
tions are based on NM_007294.3 and NM_000059.3 as
reference sequences for BRCA1 and BRCA2. To classify
variants, we followed the standards and guidelines of the
American College of Medical Genetics and Genomics
(ACMG) for the interpretation of sequence variants [11],
and all variants were scored and classified into five
pathogenicity groups (class 1: benign; class 2: likely be-
nign; class 3: uncertain significance (VUS); class 4: likely
pathogenic; class 5; pathogenic).
MLPA analyses
MLPA was performed for all Sanger sequencing-negative
patients in the LGR high-risk subgroup. MLPA probe
mixes P002 and P045 were used for screening of LGRs
in BRCA1 and BRCA2, respectively, and P087 and P077
were used for confirmation, according to the manufac-
turer’s recommendations (MRC-Holland, Amsterdam,
Netherlands). MLPA data were analyzed using Genemar-
ker v1.91 (Softgenetics, State College, PA). Peak heights
were normalized and a deletion or duplication was
defined as recommended by the manufacturer. Direct
sequencing of the probe binding and ligation sites was
performed in relevant exons to detect if any polymorph-
ism was located close to the ligation site, which may lead
to a false decrease in peak signal [4].
Statistical analyses
Categorical variables were compared using the Chi-square
test. Continuous variables were compared using the inde-
pendent samples t-test or Mann–Whitney-Wilcoxon rank
sum tests. MedCalc version 12.1.4 (MedCalc Software,




A total of 106 patients at risk of HBOC were enrolled.
All were female patients with a mean age of 51 years
and mean age at diagnosis was 48 years. Sixty-six pa-
tients (62%) were ovarian cancer cases and 40 patients
(38%) were breast cancer cases with 7 having both breast
and ovarian cancer (Table 1).
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When the patient’s risk of HBOC was stratified
according to the aforementioned high-risk criteria, 44
patients (35 breast and 9 ovarian cancer patients) were
classified as high-risk (Table 1).
BRCA1 and BRCA2 mutation screening
Of the 106 patients, Sanger sequencing identified 11 differ-
ent BRCA1 small-scale mutations in 13 patients (12%) and
6 BRCA2 small-scale mutations in 9 patients (8%) (Fig. 1).
Of the 17 BRCA1/2 small-scale mutations, 1 BRCA1
(c.2345delG) and 1 BRCA2 mutations (c.3445_3446dupAT,
n = 3) were novel, and 1 BRCA1 (c.5496_5506delGGT-
GACCCGAGinsA) and 2 BRCA2 mutations (c.1399A > T,
n = 2; c.7480C > T, n = 3) were recurrent. In addition, 13
different BRCA1 VUSs and 22 different BRCA2 VUSs
were detected and p.M784V in BRCA2 was the most com-
mon VUS (Fig. 1).
MLPA analysis of BRCA1 and BRCA2 in Sanger-
negative, high-risk patients revealed 2 previously reported
LGRs: a duplication of BRCA1 exon 4–6 and a deletion of
BRCA1 exon 19 (Fig. 2). The LGRs consisted 13% of all
identified BRCA1 mutations and the prevalence of LGRs
identified in this study was 7% in 29 Sanger-negative,
high-risk patients and 2% of all enrolled patients.
BRCA1 and BRCA2 mutation prevalence and risk factors
The overall prevalence of BRCA mutations (including
both small-scale mutations and LGRs) was 20% of all pa-
tients, 30% (12/40) for breast cancer patients, and 18%
(12/66) for ovarian cancer patients. Among patients with
personal history of breast cancer, BRCA mutations were
Table 1 Baseline characteristics of the study population
Characteristic Total Breast cancer Ovarian cancer
Number 106 40a (38%) 66 (62%)
Age, years
Mean (SD) 51 (12) 46 54
Age at diagnosis, years





Early-onset (≤36 years) 11 (28%)b
Bilateral 8 (20%)b
BC + OC 7 (18%)b
Multiple risks 9 (23%)b





BC breast cancer, OC ovarian cancer
aSeven patients had both breast and ovarian cancer
bThe percentage of patients with each high-risk feature among BC patients.
Because of rounding, the total does not equal 100%
cThe percentage of patients with high-risk feature among OC patients
dFamily history of BC and/or OC in ≥1 close blood relatives (includes first-,
second-, or third-degree relatives)
Fig. 1 Deleterious mutations (red labels) and variants of unknown significance (blue labels) of BRCA1/2 genes found in this study. The allele count
of each variant is represented by the number of black square and novel variations are underlined. Red squares represent the detected large
genomic rearrangements. Distances between variants and dimensions of each exons are not to scale
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most frequently detected in those with both breast and
ovarian cancer (43%), followed by bilateral breast cancer
(38%), and positive family history (37%). Of note,
relatively low BRCA mutation frequency was found in
patients with early-onset breast cancer (18%). And
among patients with personal history of ovarian cancer,
BRCA mutations were found in 55% of those patients
with the single high-risk criterion of positive family
history (Table 2).
Although not statistically significant, each of the high-
risk features was more commonly observed in the muta-
tion positive group than in the mutation negative group,
except for the high-risk feature of early-onset in breast
cancer patients. When the presence of at least one of
these high-risk features are compared between the muta-
tion positive group and the mutation negative group, the
proportion of patients with at least one high-risk was
twice as high in the mutation positive group (71%) than
in the mutation negative group (35%), with statistical
significance (P = 0.0326).
Risk characteristics of Korean patients with LGR
The two patients identified in this study with LGRs all
had at least one high-risk feature (Fig. 3). The index
patient with a duplication of BRCA1 exon 4–6 was diag-
nosed at the age of 67 with invasive serous epithelial
ovarian cancer, had 2 close blood relatives with breast
and/or epithelial ovarian cancer and also had 2 close
blood relatives with cancers other than breast or ovary.
The index patient with a deletion of BRCA1 exon 19
had a personal history of early-onset, bilateral, triple-





Fig. 2 The 2 BRCA1 LGRs identified in the study using MLPA. (a, b) MLPA analysis of the patient who carries duplication of BRCA1 exon 4-6. (c, d)
MLPA analysis of the patient who carries deletion of BRCA1 exon 19
Table 2 Risk characteristics of patients with small-scale








Number 82 22 2
Age, years
Mean (SD) 51 (13) 51 (9) 55 (18)
Age at diagnosis, years
Mean (SD) 48 (12) 48 (9) 49 (25)
BC 28 11 1




12 6 1 0.5804
Early-onset
(≤ 36 years)
9 1 1 0.5365
Bilateral 5 2 1 0.9313
BC + OC 4 3 0.7164
Multiple risk 9 4 1








29 15 2 0.0326
BC breast cancer, OC ovarian cancer
Bold numbers represent statistical significance
aBoth small-scale mutation and large genomic rearrangement negative
bFor a test of the hypothesis that the frequency of each high-risk fea-
ture in mutation negative and mutation positive group is equal
cThe percentage of patients with high-risk feature among OC patients
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breast cancer and also had 7 close blood relatives with
cancers other than breast or ovary.
Also, when mutation probabilities were retrospectively
calculated in previously reported Korean LGR probands
[12–14] including our 2 newly identified cases by BRCA-
PRO [15–17] and Korean hereditary breast cancer study
BRCA risk calculator (KOHCal) [18], 67% of patients
presented with BRCAPRO mutation probability >10%
and 100% of patients presented with KOHCal mutation
probability of >10%. Moreover, all reported LGRs in
Korea were detected in patients with at least one high-
risk feature (Table 3).
Discussion
In this report of 106 consecutive Korean patients at risk for
HBOC from a single center cohort, we identified 2 LGRs in
Sanger-negative, high-risk patients. Also, 11 BRCA1 and 6
BRCA2 small-scale mutations were identified and our re-
port extends the spectrum of BRCA mutations by detecting
two novel frame-shift mutations in BRCA1/2. The overall
prevalence of BRCA mutations was 20% for all patients,
30% for breast cancer, and 18% for ovarian cancer patients.
The frequency of mutations was related to the type as
well as the number of risk factors. Strong predictors of the
likelihood of carrying a BRCA mutation in patients with
personal history of breast cancer were the occurrence of
both breast and ovarian cancer (43%), bilateral breast can-
cer (38%), and positive family history (37%), and the pres-
ence of positive family history (55%) in patients with
personal history of ovarian cancer. However, there was no
difference between the proportion of early-onset breast
cancer patients between the mutation positive group and
the mutation negative group. Furthermore, all of the BRCA
mutation-positive patients with early-onset breast cancer,
had multiple risk factors other than early-onset. This is in
agreement with earlier reports that in Korean, non-familial,
early-onset breast cancer patients without other risk factors,
the prevalence of BRCA mutation is low [3, 18].
a b
Fig. 3 Pedigree of the 2 patients with large genomic rearrangements identified in this study. (a) A patient with a duplication of BRCA1 exon 4-6
and (b) a patient who carried a deletion of BRCA1 exon 19
Table 3 Risk characteristics of BRCA1 large genomic rearrangements reported in Korea
Exon rearrangement primary
cancer
Age (at Dx) FHx High risk features BRCAPRO KOHCal Detection
method
Reference
Duplication of exon 4–6 OC 35 1 BC, 1 OC, 2 COBO Strong FHx 0.7296 NA MLPA This study
Deletions of exon 10–12 BC 35 2 BC Early-onset BC Strong FHx 0.2635 69.3 MLPA, long PCR 10
Deletions of exon 12–14 BC 35 1 BC, 1 OC Early-onset BC Strong FHx 0.4352 33.4 MLPA 10
Deletions of exon 12–14 BC 49 2 BC, 1 COBO Early-onset BC Strong FHx 0.0015 19.0 MLPA, long PCR 9
Deletion of exon 19 BC 31 2 BC, 7 COBO Early-onset BC Bilateral
BC Strong FHx
0.0961 76.9 MLPA This study
Deletions of exon 1–23 BC 36 4 BC Strong FHx 0.8132 30.4 MLPA 10
Deletions of exon 1–23 BC NA NA NA NA NA MLPA 1
BC breast cancer, OC ovarian cancer, COBO cancers other than breast or ovary, Dx diagnosis, FHx family, MLPA multiplex ligation-dependent probe amplification,
NA not available
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The most important finding of this study is that se-
lective screening of high-risk, Sanger-negative Korean
patients for LGRs using MLPA analysis, identified 2
patients with LGRs in BRCA1. The LGRs comprised
2% of all enrolled patients but accounted for 7% of
Sanger-negative, high-risk patients and 12% of all
identified BRCA mutations in high-risk patients. The
frequency of LGR varies considerably among popula-
tions, with LGRs accounting for one third of BRCA1
mutations in northern Italy, and 27–36% of BRCA1
mutations in Netherlands, but less common in other
populations [9]. LGRs in BRCA are considered to be
rare in Korea, with a reported frequency of 0.45% in
familial breast cancer patients [12] and 2.1% in
Sanger-negative, familial breast cancer patients [14].
And, only 5 LGR cases have been reported so far in
Korea [3]. However, the characterization of risk char-
acteristics of LGRs in any given population allows a
more efficient and cost-effective mutational screening
approach. Our results suggest that risk stratification
and selectively screening Sanger-negative, high-risk
patients for LGRs is an effective screening strategy for
LGR detection in Korean patients. And with emerging
therapies, such as poly ADP ribose polymerase inhibitors
in combination with conventional treatment [19], a com-
prehensive genetic evaluation strategy encompassing
LGRs as well as small-scale mutations has become even
more critical.
This study has certain limitations. We did not per-
form MLPA for all Sanger-negative patients, but only
in high-risk patients, and the number of LGR cases is
limited. And since, Sanger-negative, non-high-risk pa-
tients were not included in the MLPA analysis, the
true frequency of LGRs may be greater than the re-
ported 2% of all enrolled patients. However, previous
reports have indicated that patients harboring LGR
appears to be at the highest end of the range of risks
associated with BRCA mutation [5, 9], and the prob-
ability of an LGR among non-high-risk patients can
be regarded as significantly low. Whereas the present
study is limited by small sample size and was not de-
signed to provide a comprehensive survey of the fre-
quency of LGRs, our data suggest that in high-risk
families with a negative Sanger sequencing result, LGRs
represent a significant source of BRCA mutations.
Conclusions
In summary, we have applied a simple LGR risk criteria,
and have shown that screening Sanger-negative high-risk
patients for LGR is an effective and necessary genetic
testing strategy in Korean patients. Based on the results
of this study, risk stratification of at risk patients for
HBOC and selective screening for LGRs in BRCA1 is
recommended for Korean patients.
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